NCT06163924 The Effect of Multidisciplinary Care Approach on CV Risk Modification in CaP Patients Receiving ADT
| NCT ID | NCT06163924 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Cardiovascular Risk |
| Study Type | OBSERVATIONAL |
| Enrollment | 130 participants |
| Start Date | 2023-12-10 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 130 participants in total. It began in 2023-12-10 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prostate cancer is characterised by its slow progression nature, and even for metastatic disease, the 5-year survival is up to 30%. While ADT can effectively control disease, there is increasing evidence suggesting that it can also result in many adverse cardiovascular side effects on the patients, and these effects are particularly important due to the prolonged survival of these patients. There are suggestions that close cardiovascular (CV) monitoring will help to reduce cardiovascular risk and related morbidities. However, there is limited data to show the positive impact of these monitoring could reducing CV risk and morbidities. Moreover, information regarding the optimal follow-up approach and schedule is also lacking. Therefore, there is a need to have more information on the approach to monitoring the CV risk and the real-life impact of this monitoring on our patients. Patients diagnosed with prostate cancer and plan to receive ADT are invited to participate in this study to assess the potential benefit of multidisciplinary care approach to CV risk modification.
Eligibility Criteria
Inclusion Criteria: * Adult men 18-80 years old * With histological proven prostate cancer or clinically diagnosed to have prostate cancer, * Planned for ADT for at least 1 year Exclusion Criteria: * Subjects with established major atherosclerotic cardiovascular disease (ASCVD) as defined by a recent acute coronary syndrome within the past 12 months, a history of myocardial infarction other than the recent acute coronary syndrome event, a history of ischemic stroke, and symptomatic peripheral arterial disease (defined as history of claudication with ankle-brachial index \<0.85 or previous revascularization or amputation * Prior neoadjuvant or adjuvant hormone therapy within 1 year before * Refuse or unable to give written informed consent * Participation in an investigational program with interventions outside of routine clinical practice
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06163924 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 80 Years, studying Cardiovascular Risk. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06163924 currently recruiting?
Yes, NCT06163924 is actively recruiting participants. Contact the research team at ngcf@surgery.cuhk.edu.hk for enrollment information.
Where is the NCT06163924 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT06163924 clinical trial?
NCT06163924 is sponsored by Chinese University of Hong Kong. The trial plans to enroll 130 participants.